Relay Therapeutics, Inc.
RLAY
Hisse Senetlerindeki Sıralama
#4225
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Hisse Fiyatı
$17.16
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$3.76B
Değişim (1 gün)
5.41%
Değişim (1 yıl)
140.34%
Ülke
US
Ticaret Relay Therapeutics, Inc. (RLAY)
Kategori
Healthcare
Relay Therapeutics, Inc. (RLAY) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-286.04M
Relay Therapeutics, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-286.04M'dir. 2023 yılında şirket $-341.97M kazanç elde etti, bu 2022 yılındaki $-290.51M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Relay Therapeutics, Inc. için kazanç geçmişi 2018 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-286.04M | -15.30% |
| 2024 | $-337.71M | -1.25% |
| 2023 | $-341.97M | 17.72% |
| 2022 | $-290.51M | -20.16% |
| 2021 | $-363.87M | 594.25% |
| 2020 | $-52.41M | -30.40% |
| 2019 | $-75.31M | 54.36% |
| 2018 | $-48.79M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -1,944.13% |
US
|
|
| $-3.09B | 979.23% |
US
|
|
| $-4.02B | 1,304.08% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -781.96% |
NL
|
